Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

Clinical trial NCT05359146 · UNKNOWN

Trial details

NCT number: NCT05359146
Sponsor: University Hospital, Basel, Switzerland
Status: UNKNOWN
Phase: Early Phase 1
Study type: INTERVENTIONAL

Neuroendocrine Neoplasia's (NENs)Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Start date: 2023-03-28
Primary completion: 2025-12-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.